ArticleScience advances2023
An ultrasound-activatable platinum prodrug for sono-sensitized chemotherapy.
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Modern Cyanine Dye-Based Photosensitizers for Medical Applications.Angewandte Chemie (International ed. in English) · 2026Review
- Nanocarrier-based delivery of Pt(IV) compounds for chemoimmunotherapy and theranostics: Advances, challenges, and prospects.Acta pharmaceutica Sinica. B · 2026Review
- A Deep-Red-Absorbing Osmium(II) Complex as a Photosensitizer for Photodynamic Therapy Inducing Immunogenic Cell Death.Angewandte Chemie (International ed. in English) · 2026Article
- Activatable smart contrast agents for photoacoustic imaging.Smart molecules : open access · 2026Review
- Metal complexes in medicine: structural scaffoldsChemical science · 2026Review
- Precise delivery and controlled release: strategies and advances in TLR7/8 agonist prodrugs for cancer immunotherapy.Frontiers in immunology · 2026Review
- Controlled Dual Activation of Rhenium(I) Photosensitizers and Profluorophores/Prodrugs via a Dissociative Bioorthogonal Tetrazine-Isonitrile Reaction.Angewandte Chemie (International ed. in English) · 2025Article
- Ultrasound-activatable transition metal complexes to potentiate sonodynamic therapy.Chemical science · 2025Review
- Unified linear-concave transducer enabling 100 Hz plane-wave ultrasound and photoacoustic dynamic imaging.Biomedical optics express · 2025Article
- Prodrug nanosystem equipped with a sonosensitizer for combined chemotherapy and sonodynamic therapy of melanoma.Materials today. Bio · 2025Article
- Radiotherapy-Activated Prodrug: Past, Present and Beyond.ACS central science · 2025Review
- Prodrug Strategy for PROTACs: High Efficiency and Low Toxicity.ACS omega · 2025Review
- Ultrasound-Responsive 4D Bioscaffold for Synergistic Sonopiezoelectric-Gaseous Osteosarcoma Therapy and Enhanced Bone Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Ultrasound-induced single-electron reduction of azide groups in aromatic prodrugs.National science review · 2025Article
- Tandem activated caged galactoside prodrugs: advancing beyond single galactosidase dependence.Chemical science · 2025Article
- PEGylation Effects on Amphiphilic Platinum(IV) Complexes: Influence on Uptake, Activation, and Cytotoxicity.Pharmaceutics · 2025Article
- New horizons for the therapeutic application of nanozymes in cancer treatment.Journal of nanobiotechnology · 2025Review
- Nucleotide coordinated polymers, a ROS-based immunomodulatory antimicrobial, doubly killBioactive materials · 2025Article
- Ultrasound-Controlled Prodrug Activation: Emerging Strategies in Polymer Mechanochemistry and Sonodynamic Therapy.ACS applied bio materials · 2024Review
- Sonopharmacology: Regulation of drug activity through ultrasound.Journal of pharmaceutical analysis · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the great success achieved by photoactivated chemotherapy, eradicating deep tumors using external sources with high tissue penetration depth remains a challenge. Here, we present cyaninplatin, a paradigm of Pt(IV) anticancer prodrug that can be activated by ultrasound in a precise and spatiotemporally controllable manner. Upon sono-activation, mitochondria-accumulated cyaninplatin exhibits strengthened mitochondrial DNA damage and cell killing efficiency, and the prodrug overcomes drug resistance as a consequence of combined effects from released Pt(II) chemotherapeutics, the depletion of intracellular reductants, and the burst of reactive oxygen species, which gives rise to a therapeutic approach, namely sono-sensitized chemotherapy (SSCT). Guided by high-resolution ultrasound, optical, and photoacoustic imaging modalities, cyaninplatin realizes the overall theranostics of tumors in vivo with superior efficacy and biosafety. This work highlights the practical utility of ultrasound to precisely activate Pt(IV) anticancer prodrugs for the eradication of deep tumor lesions and broadens the biomedical uses of Pt coordination complexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.